{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:04:45Z","timestamp":1792267485981,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T00:00:00Z","timestamp":1425859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T00:00:00Z","timestamp":1425859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The advent of anti-tumor necrosis factor alpha (anti-TNF\u03b1) drugs has considerably improved medical management in rheumatoid arthritis (RA) patients, although it has been reported to be ineffective in a fraction of them. MicroRNAs (miRNAs) are small, non-coding RNAs that act as fine-tuning regulators of gene expression. Targeting miRNAs by gain or loss of function approaches have brought therapeutic effects in various disease models. The aim of this study was to investigate serum miRNA levels as predictive biomarkers of response to anti-TNF\u03b1 therapy in RA patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>In total, 95 RA patients undergoing anti-TNF\u03b1\/disease-modifying antirheumatic drugs (anti-TNF\u03b1\/DMARDs) combined treatments were enrolled. Serum samples were obtained at 0 and 6\u00a0months and therapeutic efficacy was assessed. miRNAs were isolated from the serum of 10 patients before and after anti-TNF\u03b1\/DMARDs combination therapy, cDNA transcribed and pooled, and human serum miRNA polymerase chain reaction (PCR) arrays were performed. Subsequently, selected miRNAs were analyzed in a validation cohort consisting of 85 RA patients. Correlation studies with clinical and serological variables were also performed.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Ninety percent of RA patients responded to anti-TNF\u03b1\/DMARDs combination therapy according to European League Against Rheumatism (EULAR) criteria. Array analysis showed that 91% of miRNAS were overexpressed and 9% downregulated after therapy. Functional classification revealed a preponderance of target mRNAs involved in reduction of cells maturation - especially on chondrocytes - as well as in immune and inflammatory response, cardiovascular disease, connective tissue and musculoskeletal system. Six out of ten miRNAs selected for validation were found significantly upregulated by anti-TNF\u03b1\/DMARDs combination therapy (miR-16-5p, miR-23-3p, miR125b-5p, miR-126-3p, miRN-146a-5p, miR-223-3p). Only responder patients showed an increase in those miRNAs after therapy, and paralleled the reduction of TNF\u03b1, interleukin (IL)-6, IL-17, rheumatoid factor (RF), and C-reactive protein (CRP). Correlation studies demonstrated associations between validated miRNAs and clinical and inflammatory parameters. Further, we identified a specific plasma miRNA signature (miR-23 and miR-223) that may serve both as predictor and biomarker of response to anti-TNF\u03b1\/DMARDs combination therapy.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>miRNA levels in the serum of RA patients before and after anti-TNF\u03b1\/DMARDs combination therapy are potential novel biomarkers for predicting and monitoring therapy outcome.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0555-z","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T11:58:11Z","timestamp":1425643091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF\u03b1"],"prefix":"10.1186","volume":"17","author":[{"given":"Carmen","family":"Castro-Villegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Filipescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Verdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ruiz-Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Angeles","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Jim\u00e9nez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rodriguez-Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ramon","family":"Peinado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Collantes-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Gonz\u00e1lez-Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantino","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Barbarroja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chary","family":"L\u00f3pez-Pedrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,9]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/11631480-000000000-00000","volume":"26","author":"M Filkov\u00e1","year":"2012","unstructured":"Filkov\u00e1 M, J\u00fcngel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs. 2012;26:131\u201341.","journal-title":"BioDrugs."},{"key":"555_CR2","first-page":"1204","volume":"10","author":"F Atzeni","year":"2009","unstructured":"Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs. 2009;10:1204\u201311.","journal-title":"Curr Opin Investig Drugs."},{"key":"555_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907\u201316.","journal-title":"N Engl J Med."},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11:S1.","journal-title":"Arthritis Res Ther."},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2217\/pgs.11.114","volume":"12","author":"R Prajapati","year":"2011","unstructured":"Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011;12:1571\u201385.","journal-title":"Pharmacogenomics."},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/BOR.0b013e3282f5135b","volume":"20","author":"RM Plenge","year":"2008","unstructured":"Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol. 2008;20:145\u201352.","journal-title":"Curr Opin Rheumatol."},{"key":"555_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/rheumatology\/ket017","volume":"52","author":"SB Krintel","year":"2013","unstructured":"Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford). 2013;52:1245\u201353.","journal-title":"Rheumatology (Oxford)."},{"key":"555_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jprot.2012.09.011","volume":"77","author":"I Ortea","year":"2012","unstructured":"Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonz\u00e1lez I, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics. 2012;77:372\u201382.","journal-title":"J Proteomics."},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11926-013-0372-9","volume":"15","author":"N Bottini","year":"2013","unstructured":"Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep. 2013;15:372.","journal-title":"Curr Rheumatol Rep."},{"key":"555_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/ar3377","volume":"13","author":"A Ceribelli","year":"2011","unstructured":"Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther. 2011;13:229.","journal-title":"Arthritis Res Ther."},{"key":"555_CR11","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar2493","volume":"10","author":"KM Pauley","year":"2008","unstructured":"Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10:R101.","journal-title":"Arthritis Res Ther."},{"key":"555_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1471-2474-11-209","volume":"11","author":"T Niimoto","year":"2010","unstructured":"Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2010;11:209.","journal-title":"BMC Musculoskelet Disord."},{"key":"555_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/art.23386","volume":"58","author":"J Stanczyk","year":"2008","unstructured":"Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58:1001\u20139.","journal-title":"Arthritis Rheum."},{"key":"555_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/art.24475","volume":"60","author":"Y Nakamachi","year":"2009","unstructured":"Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, Chin T, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009;60:1294\u2013304.","journal-title":"Arthritis Rheum."},{"key":"555_CR15","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/art.30321","volume":"63","author":"T Nakasa","year":"2011","unstructured":"Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum. 2011;63:1582\u201390.","journal-title":"Arthritis Rheum."},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar3013","volume":"12","author":"K Murata","year":"2010","unstructured":"Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12:R86.","journal-title":"Arthritis Res Ther."},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"2010","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;2010:2569\u201381.","journal-title":"Arthritis Rheum."},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/acr.22151","volume":"66","author":"JS Chen","year":"2014","unstructured":"Chen JS, Makovey J, Lassere M, Buchbinder R, March LM. Comparative effectiveness of anti-tumour necrosis factor (TNF) drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014;66:464\u201372.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"555_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","volume":"26","author":"MW Pfaffl","year":"2004","unstructured":"Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper \u2013 Excel-based tool using pair-wise correlations. Biotechnol Lett. 2004;26:509\u201315.","journal-title":"Biotechnol Lett."},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43:447\u201357.","journal-title":"Semin Arthritis Rheum."},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/ar2592","volume":"11","author":"MB Goldring","year":"2009","unstructured":"Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther. 2009;11:224.","journal-title":"Arthritis Res Ther."},{"key":"555_CR22","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1186\/ar2850","volume":"11","author":"C Csaki","year":"2009","unstructured":"Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11:R165.","journal-title":"Arthritis Res Ther."},{"key":"555_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trsl.2012.04.002","volume":"160","author":"H Wang","year":"2012","unstructured":"Wang H, Peng W, Ouyang X, Li W, Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 2012;160:198\u2013206.","journal-title":"Transl Res."},{"key":"555_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/ar4194","volume":"15","author":"X Luo","year":"2013","unstructured":"Luo X, Ranade K, Talker R, Jallal B, Shen N, Yao Y. microRNA-mediated regulation of innate immune response in rheumatic diseases. Arthritis Res Ther. 2013;15:210.","journal-title":"Arthritis Res Ther."},{"key":"555_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.278.5339.860","volume":"278","author":"F Mercurio","year":"1997","unstructured":"Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278:860\u20136.","journal-title":"Science."},{"key":"555_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/14397595.2014.950035","volume":"25","author":"M Ohtsuji","year":"2015","unstructured":"Ohtsuji M, Lin Q, Nishikawa K, Ohtsuji N, Okazaki H, Tsurui H, et al. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel Fc\u03b3RIIB-deficient rheumatoid arthritis mouse model. Mod Rheumatol. 2015;25:270\u20137.","journal-title":"Mod Rheumatol."},{"key":"555_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2008.08.036","volume":"204","author":"VF Panoulas","year":"2009","unstructured":"Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, et al. Association of interleukin-6 (IL-6)-174G\/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2009;204:178\u201383.","journal-title":"Atherosclerosis."},{"key":"555_CR28","doi-asserted-by":"publisher","first-page":"31444","DOI":"10.1074\/jbc.M910132199","volume":"275","author":"D Chikazu","year":"2000","unstructured":"Chikazu D, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T, et al. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42\/p44 MAP kinase. J Biol Chem. 2000;275:31444\u201350.","journal-title":"J Biol Chem."},{"key":"555_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.berh.2006.06.009","volume":"20","author":"FP Luyten","year":"2006","unstructured":"Luyten FP, Lories RJ, Verschueren P, de Vlam K, Westhovens R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol. 2006;20:829\u201348.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"555_CR30","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ajpath.2012.01.030","volume":"180","author":"B Bartok","year":"2012","unstructured":"Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, et al. PI3 kinase \u03b4 is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol. 2012;180:1906\u201316.","journal-title":"Am J Pathol."},{"key":"555_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1755-5922.2010.00206.x","volume":"29","author":"A Eisenreich","year":"2011","unstructured":"Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther. 2011;29:29\u201336.","journal-title":"Cardiovasc Ther."},{"key":"555_CR32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/art.21897","volume":"54","author":"RJ Lories","year":"2006","unstructured":"Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006;54:1736\u201346.","journal-title":"Arthritis Rheum."},{"key":"555_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/03009742.2013.805241","volume":"43","author":"M Korkosz","year":"2014","unstructured":"Korkosz M, G\u0105sowski J, Leszczy\u0144ski P, Pawlak-Bu\u015b K, Jeka S, Siedlar M, et al. Effect of tumour necrosis factor-\u03b1 inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol. 2014;43:43\u20138.","journal-title":"Scand J Rheumatol."},{"key":"555_CR34","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/annrheumdis-2012-202815","volume":"73","author":"M Filkov\u00e1","year":"2014","unstructured":"Filkov\u00e1 M, Aradi B, Senolt L, Ospelt C, Vettori S, Mann H, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis. 2014;73:1898\u2013904.","journal-title":"Ann Rheum Dis."},{"key":"555_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1196\/annals.1443.009","volume":"1143","author":"KM Pauley","year":"2008","unstructured":"Pauley KM, Chan EK. MicroRNAs and their emerging roles in immunology. Ann N Y Acad Sci. 2008;1143:226\u201339.","journal-title":"Ann N Y Acad Sci."},{"key":"555_CR36","doi-asserted-by":"crossref","unstructured":"Zhou Q, Haupt S, Kreuzer JT, Hammitzsch A, Proft F, Neumann C, et al. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis. 2014; doi:10.1136\/annrheumdis-2013-204377. [Epub ahead of print].","DOI":"10.1136\/annrheumdis-2013-204377"},{"key":"555_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjd.12381","volume":"169","author":"A Pivarcsi","year":"2013","unstructured":"Pivarcsi A, Meisgen F, Xu N, St\u00e5hle M, Sonkoly E. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-\u03b1 therapy. Br J Dermatol. 2013;169:563\u201370.","journal-title":"Br J Dermatol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0555-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0555-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:32:15Z","timestamp":1728923535000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0555-z","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,9]]},"assertion":[{"value":"7 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}